At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 37 enrolled
Drug / intervention
Abraxane +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Phase II Study of Abraxane and Gemicitabine in Patients With Advanced Adenocarcinoma Non-Small Cell Lung Cancer Progressing After First-Line Platinum-Based Chemotherapy
In Brief
A Phase 2 clinical trial evaluating Abraxane and Gemcitabine for Patients With Stage IV or Recurrent Adenocarcinoma of the Lung. Completed, enrolled 37 participants.
Detailed Summary
The main purpose of this study is to see how well the combination of Abraxane and gemcitabine works in people with advanced adenocarcinoma NSCLC who have already had treatment for their disease. Gemcitabine and Abraxane are FDA approved chemotherapies; however, the FDA has not approved this combination in the treatment of this specific type of cancer. Patients may continue to receive the study drugs until their disease gets worse or they have unacceptable side effects.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
Countries--
Collaborators--
Timeline
Phase 2CompletedFinished
201520162017201820192020202120222023202420252026
First PostedDec 2014
Enrollment StartJun 2015
Primary CompletionApr 2020
TodayJul 2026
First PostedDec 1, 2014
Enrollment StartJun 26, 2015
Primary CompletionApr 30, 2020
TodayJul 2, 2026
Enrollment to primary: 4.8 yearsPosted 11.6 years ago
Interventions
Abraxanedrug
Gemcitabinedrug